Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: BG00002 (natalizumab)
- First Posted Date
- 2008-05-09
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 6
- Registration Number
- NCT00675428
- Locations
- 🇺🇸
Research Center, Rochester, Minnesota, United States
A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors
- Conditions
- Solid Tumors
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 55
- Registration Number
- NCT00674947
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Baminercept alfa (BG9924)
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 339
- Registration Number
- NCT00664573
- Locations
- 🇬🇧
Coordinating Research Site, Leeds, Yorkshire, United Kingdom
Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Baminercept alfa 3Biological: Baminercept alfa 1Biological: Baminercept alfa 5Biological: PlaceboBiological: Baminercept alfa 2Biological: Baminercept alfa 4
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 391
- Registration Number
- NCT00664716
- Locations
- 🇬🇧
Coordinating Research Site, Leeds, Yorkshire, United Kingdom
Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT00651443
- Locations
- 🇺🇸
Research Site, Buffalo, New York, United States
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT00618319
- Locations
- 🇺🇸
Research Site, Santa Monica, California, United States
🇺🇸Reseach Facility, San Antonio, Texas, United States
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 68
- Registration Number
- NCT00618735
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 100
- Registration Number
- NCT00618267
- Locations
- 🇺🇸
Brigham and Women's Hospital - Partners MS Center, Brookline, Massachusetts, United States
A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis
- Conditions
- Active Ulcerative Colitis
- Interventions
- Drug: PlaceboDrug: BG9418 (Interferon beta-1a)
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 123
- Registration Number
- NCT00616434
- Locations
- 🇸🇰
Investigator, Trencin, Slovakia
🇷🇺Investiator, Yaroslavl, Russian Federation
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2010-01-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 136
- Registration Number
- NCT00599274
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
🇨🇦Coordinating Research Site, Halifax, Nova Scotia, Canada